Picard Medical/ SynCardia to Present at European Mechanical Circulatory Support Summit and International Course on Mechanical Circulatory Support and New Technologies in Heart Failure

Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, is set to showcase advancements in heart technology at the upcoming 19th European Mechanical Circulatory Support Summit (EUMS) and the 11th International Course on Mechanical Circulatory Support and New Technologies in Heart Failure. Dr. Andre Simon, Vice President of Clinical Affairs at Picard, will present vital data on the Emperor Total Artificial Heart (TAH), recognized as the first fully implantable artificial heart approved by both the U.S. FDA and Health Canada.

The summit will occur from February 15 to 18, 2026, in Barcelona, Spain, bringing together key figures in the medical community, including clinicians, researchers, and industry leaders. The event aims to foster collaboration and innovation in mechanical circulatory support, addressing critical advancements in the treatment of advanced heart failure (HF). Dr. Simon's presentation, titled "The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart," is scheduled for February 16, 2026, from 17:15 to 18:15 Central European Time.

Picard Medical, along with its subsidiary SynCardia, specializes in developing and commercializing the SynCardia Total Artificial Heart (STAH), which is critically designed for patients suffering from end-stage heart failure. With over 2,100 implants across 27 countries, SynCardia's technology stands as the only commercially available artificial heart in the U.S. and Canada, solidifying its position as a leader in the field. The participation in EUMS highlights the ongoing commitment to innovation and the advancement of heart failure treatment, providing insights into the future of mechanical support technologies.

For further details about Picard Medical, interested individuals can visit their website or consult their filings with the U.S. Securities and Exchange Commission.

As of February 10, 2026, Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, is poised for significant visibility at the upcoming European Mechanical Circulatory Support Summit (EUMS) and International Course on Mechanical Circulatory Support in Barcelona. Dr. Andre Simon's presentation on the Emperor Total Artificial Heart (TAH)—an innovative, fully implantable device approved by both the FDA and Health Canada—highlights the company's pivotal role in transforming heart failure treatment.

Investors should approach PMI with cautious optimism. The company capitalizes on a niche market as the only provider of commercially available total artificial heart technology, which could be an attractive proposition for portfolio diversification. The growing global prevalence of heart failure, coupled with an emphasis on advanced therapeutic options, positions SynCardia for potential market expansion. The scientific discussions and collaboration at the EUMS are crucial for fostering relationships with clinicians and researchers, potentially leading to clinical partnerships and further advancements in their offerings.

However, investors should remain aware of potential risks. Regulatory challenges are a continuous concern in the medical device sector, and reliance on a single core product can expose PMI to significant business risk, especially if competitors emerge with alternative solutions. It’s critical to monitor the reception of the Emperor TAH post-presentation: investor sentiment may swing based on the clinical efficacy data and competitive landscape highlighted at the conference.

In summary, while the upcoming presentation could be a catalyst for growth, vigilant investors should weigh the innovative advancements against potential market competition and regulatory hurdles. Establishing a watchful approach toward Picard Medical is advisable, emphasizing both growth prospects and the inherent risks of the medical technology sector.